Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting
18 Juli 2023 - 2:00PM
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage
pharmaceutical company committed to the global development and
commercialization of cytisinicline for smoking cessation and
nicotine dependence, today announced participation on a panel
during the 2023 American Society of Pharmacognosy (ASP) Annual
Meeting, being held at the Bethesda North Marriott Hotel Conference
Center in Rockville, MD from July 22-26, 2023.
Achieve management, John Bencich, Chief Executive Officer, and
Richard Stewart, Executive Chairman of the Board of Directors, will
present on a public/private partnerships panel titled “SEEDing
Biomedical Innovation: Support for Small Businesses at National
Institute of Health” to be held on Monday, July 24, 2023, at 10:30
AM EDT.
For additional information on the 2023 ASP Annual Meeting,
including registration details, please visit the meeting
website.
About Achieve and Cytisinicline Achieve’s focus
is to address the global smoking health and nicotine addiction
epidemic through the development and commercialization of
cytisinicline. Tobacco use is currently the leading cause of
preventable death that is responsible for more than eight million
deaths worldwide and nearly half a million deaths in the United
States annually.1,2 More than 87% of lung cancer deaths, 61% of all
pulmonary disease deaths, and 32% of all deaths from coronary heart
disease are attributable to smoking and exposure to secondhand
smoke.2
In addition, there are over 11 million adults in the United
States who use e-cigarettes, also known as vaping.3 In 2022,
approximately 2.5 million middle and high school students in the
United States reported using e-cigarettes.4 Currently, there are no
FDA-approved treatments indicated specifically as an aid to
nicotine e-cigarette cessation.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in treating nicotine addiction for smoking and e-cigarette
cessation by interacting with nicotine receptors in the brain,
reducing the severity of withdrawal symptoms, and reducing the
reward and satisfaction associated with nicotine products.
Cytisinicline is an investigational product candidate being
developed for the treatment of nicotine addiction and has not been
approved by the Food and Drug Administration for any indication in
the United States.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
timing and nature of cytisinicline clinical development, data
results and commercialization activities, the potential market size
for cytisinicline, the potential benefits, safety and tolerability
of cytisinicline, the ability to discover and develop new uses for
cytisinicline, including but not limited to as an e-cigarette
cessation product, and the development and effectiveness of new
treatments. All statements other than statements of historical fact
are statements that could be deemed forward-looking statements.
Achieve may not actually achieve its plans or product development
goals in a timely manner, if at all, or otherwise carry out its
intentions or meet its expectations or projections disclosed in
these forward-looking statements. These statements are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements, including, among others, the risk that
cytisinicline may not demonstrate the hypothesized or expected
benefits; the risk that Achieve may not be able to obtain
additional financing to fund the development of cytisinicline; the
risk that cytisinicline will not receive regulatory approval or be
successfully commercialized; the risk that new developments in the
smoking cessation landscape require changes in business strategy or
clinical development plans; the risk that Achieve’s intellectual
property may not be adequately protected; general business and
economic conditions; risks related to the impact on our business of
macroeconomic conditions, including inflation, rising interest
rates, instability in the global banking sector, and public health
crises, such as the COVID-19 pandemic and the other factors
described in the risk factors set forth in Achieve’s filings with
the Securities and Exchange Commission from time to time, including
Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form
10-Q. Achieve undertakes no obligation to update the
forward-looking statements contained herein or to reflect events or
circumstances occurring after the date hereof, other than as may be
required by applicable.
Investor Relations ContactNicole
Jonesachv@cg.capital(404) 736-3838
Media ContactGlenn
SilverGlenn.Silver@Finnpartners.com(646) 871-8485
References1World Health Organization. WHO
Report on the Global Tobacco Epidemic, 2019. Geneva: World Health
Organization, 2017.2U.S. Department of Health and Human Services.
The Health Consequences of Smoking – 50 Years of Progress. A Report
of the Surgeon General, 2014.3Cornelius ME, Loretan CG, Jamal A, et
al. Tobacco Product Use Among Adults – United States, 2021. MMWR
Morb Mortal Wkly Rep 2023;72:475–483.4Park Lee E, Ren C, Cooper M,
Cornelius M, Jamal A, Cullen KA. Tobacco Product Use Among Middle
and High School Students – United States, 2022. Morbidity and
Mortality Weekly Report, 2022; 71:45.
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
Von Okt 2023 bis Okt 2024